rhG-CSF联合CHOP方案治疗非霍奇金淋巴瘤的临床效果及对患者生活质量的影响
详细信息    查看全文 | 推荐本文 |
  • 英文篇名:Efficacy of rhG-CSF combined with CHOP regimen in the treatment of non-Hodgkin lymphoma and its impact on the quality of life
  • 作者:吴萍 ; 李萍 ; 刘海宁 ; 王慧丽 ; 朱丽伟 ; 刘姗姗
  • 英文作者:WU Ping;LI Ping;LIU Hai-ning;WANG Hui-li;ZHU Li-wei;LIU Shan-shan;Department of Hematology, Sir Run Run Hospital, Nanjing Medical University;Department of Hematology, Nanjing Drum Tower Hospital;
  • 关键词:CHOP方案 ; 重组人粒细胞集落刺激因子 ; 非霍奇金淋巴瘤 ; 生活质量
  • 英文关键词:CHOP regimen;;Recombinant human granulocyte-colony stimulating factor;;Non-Hodgkin lymphoma;;Quality of life
  • 中文刊名:YXQY
  • 英文刊名:Chinese Journal of the Frontiers of Medical Science(Electronic Version)
  • 机构:南京医科大学附属逸夫医院血液科;南京鼓楼医院血液科;
  • 出版日期:2019-01-20
  • 出版单位:中国医学前沿杂志(电子版)
  • 年:2019
  • 期:v.11
  • 语种:中文;
  • 页:YXQY201901035
  • 页数:4
  • CN:01
  • ISSN:11-9298/R
  • 分类号:161-164
摘要
目的探讨重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)联合CHOP方案治疗非霍奇金淋巴瘤的临床效果及对患者生活质量的影响。方法选取2016年10月至2017年9月本院收治的非霍奇金淋巴瘤患者68例为研究对象,按照随机数表法将其分为对照组和研究组,每组各34例。对照组患者采用CHOP方案治疗,研究组患者采用rhG-CSF联合CHOP方案治疗,比较两组患者的治疗有效率、中性粒细胞绝对值(absolute neutrophil count,ANC)以及简明健康状况调查(36-item short-form general health survey,SF-36)量表评分。结果研究组患者治疗有效率明显高于对照组(50.0%︰23.5%,P <0.05)。治疗过程中,研究组患者ANC持续≤1.0×10~9/L、≤2.0×10~9/L及恢复至≥2.0×10~9/L所需天数均短于对照组,但差异无显著性(P_均> 0.05)。研究组患者ANC持续≤0.5×10~9/L及恢复至≥1.0×10~9/L所需天数均显著短于对照组(P_均<0.05)。治疗后,两组患者SF-36量表各项评分均显著高于本组治疗前(P_均<0.05),且研究组患者各项评分均显著高于对照组(P_均<0.05)。结论 rhG-CSF联合CHOP方案治疗非霍奇金淋巴瘤,可以有效缩短化疗所致中性粒细胞减少/缺乏时间,降低继发性感染风险,提高患者生活质量。
        Objective To investigate the clinical efficacy of recombinant human granulocyte-colony stimulating factor(rhG-CSF) combined with CHOP regimen in the treatment of non-Hodgkin lymphoma(NHL) and its effect on the quality of life(QOL). Method68 NHL patients treated in Sir Run Run Hospital, Nanjing Medical University from October 2016 to September 2017 were selected as the subjects. According to the random number table method, the patients were divided into control group and study group, with 34 patients in each group. Patients in control group were treated with rhG-CSF, and patients in study group were treated with rhG-CSF combined with CHOP regimen. The treatment efficiency, absolute neutrophil count(ANC) and 36-item short-form general health survey(SF-36) score were compared between the two groups. Result The effective rate of study group was significantly higher than that of control group(50.0%: 23.5%, P < 0.05). In the course of medical treatment, the duration of ANC ≤ 1.0×10~9/L, ≤ 2.0×10~9/L and the days needed to recover to ≥ 2.0×10~9/L of study group were shorter than those of control group, but there were no significant differences(P_(all)> 0.05), the duration of ANC ≤ 0.5×10~9/L and the days needed to recover to ≥ 1.0×10~9/L of study group were significantly shorter than those of control group(P_(all)< 0.05). After treatment, the scores of SF-36 in both groups were significantly higher than those before treatment(P_(all)< 0.05), and the scores of study group were significantly higher than those of control group(P_(all)< 0.05). Conclusion rh G-CSF combined with CHOP regimen in the treatment of NHL, can reduce recurrence and improve the quality of life.
引文
[1]汪靖,金润铭.不同年龄段非霍奇金淋巴瘤患者的临床病理学特征[J].新乡医学院学报,2014,31(12):1018-1021.
    [2]徐晓燕,王慧睿,郭淑丽,等.侵袭性非霍奇金淋巴瘤患者化疗前CD4+与CD8+水平对化疗后感染及疗效的相关性研究[J].中华医院感染学杂志,2016,26(12):2758-2760.
    [3]张美霞,徐细明.乙肝病毒感染与B淋巴瘤患者利妥昔单抗联合CHOP化疗后的临床观察[J].山西医科大学学报,2015,46(7):613-616.
    [4]中国医师协会肿瘤医师分会.中国重组人粒细胞集落刺激因子在肿瘤化疗中的临床应用专家共识(2015年版)[J].中华医学杂志,2015,95(37):3001-3003.
    [5]李佳,张嵘,胡荣,等.ESHAP方案治疗复发、难治性非霍奇金淋巴瘤疗效观察[J].山东医药,2015,55(15):44-45.
    [6]张端众,肖青,张红宾,等.自体外周血造血干细胞移植治疗非霍奇金淋巴瘤56例临床分析[J].重庆医科大学学报,2015,40(1):154-158.
    [7]王山,樊文洁,俞婉琦,等.SF-36量表应用于城市化居民生命质量评价的信度和效度分析[J].中华流行病学杂志,2016,37(3):344-347.
    [8]杨小芸,沈丽达,龙庭凤,等.1326例非霍奇金淋巴瘤临床病理特点分析[J].中华肿瘤防治杂志,2016,23(9):605-609.
    [9]黎纬明,邹萍.非霍奇金淋巴瘤的诊断与治疗进展[J].临床内科杂志,2015,32(3):149-151.
    [10]李春艳,薛恺,张群岭,等.聚乙二醇化重组人G-CSF在vRCHOP为基础方案的非霍奇金淋巴瘤中的应用[J].中国癌症杂志,2017,27(12):970-975.
    [11]Chao C,Rodriguez R,Page JH,et al.History of chronic como rbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granu locyte colony-stimulating factor prophylaxis[J].Leuk Lymphoma,2015,56(1):72-79.
    [12]刘凯,杨曼曼,刘德果,等.六味地黄丸联合CHOP方案治疗非霍奇金淋巴瘤的临床观察[J].中医药导报,2017,23(3):56-58.
    [13]Wildes TM,Cashen A.High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma:Feasible,but for which patients?[J].JGeriatr Oncol,2015,6(5):344-345.
    [14]王彩丽,张景荣,杨莹.感染相关中性粒细胞减少症122例临床分析[J].贵阳医学院学报,2014,39(1):111-112.
    [15]吴凤鹏,吴凤云,王军,等.PEG-rhG-CSF对Ⅲ度中性粒细胞减少患者粒细胞增殖状况的研究[J].中国新药杂志,2014,23(9):1066-1069.
    [16]徐兵河,宋艳秋,王京芬,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅱ期临床研究[J].中国肿瘤临床与康复,2016,38(1):3-7.
    [17]杨付珍,王开云,田智萍,等.CTOP与CHOP方案治疗老年初治非霍奇金淋巴瘤的临床对照研究[J].海南医学,2018,29(3):309-312.
    [18]石瑞平,郭树霞,范玮.R-CHOP化疗方案治疗B细胞非霍奇金淋巴瘤的疗效及预后分析[J].临床医学,2018,38(3):95-97.
    [19]李敬东,韩效林,杨翠,等.DLBCL患者CHOP或R-CHOP化疗前后中性粒细/淋巴细胞比值的变化及其对生存的影响[J].中国实验血液学杂志,2018,26(1):182-186.
    [20]邹中辉,张传蓉,等.利妥昔单抗联合改良CHOP方案对胃肠道非霍奇金淋巴瘤的临床疗效及安全性分析[J].中国药业,2017,26(15):61-63.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700